Ovarian Cancer Research Benefits from First Certara Biomedical Research Scholarship

Ovarian Cancer Research Benefits from First Certara Biomedical Research Scholarship
The first Certara Biomedical Research Scholarship has been awarded to the National Institutes of Health (NIH)'s National Center for Advancing Translational Science (NCATS) to support a research project focusing on ovarian cancer cellular aggregates (spheroids) that often lead to metastasis and cancer relapse following surgery. The research is being led by postgraduate research student David Morse. “We are delighted to support Mr. Morse’s ovarian cancer research and the NIH Oxford-Cambridge Scholars Program in which he also participates,” Dr. Edmundo Muniz, PhD, Certara's CEO, said in a press release. “At Certara, we are committed to scientific education and to leveraging modeling and simulation to develop novel therapies for cancer. This scholarship, along with our recent appointment of Adam Darwich, PhD, as the first Certara Lecturer in Precision Dosing at The University of Manchester in England, affirm our beliefs in education and innovation.” Modeling and simulation are well-validated methods used to identify biomarkers that predict anti-tumor activity, both to determine the best dosing approaches and the potential for drug interactions when therapies are combined. In his research, Morse is using single-cell RNA sequencing. His aim is to explore cellular differences of ovarian cancer spheroids and identify genes that are differentially expressed, functional, and targetable. “These spheroids remain within patients after surgical resection of primary ovarian cancer tumors, and are thought to lead to
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *